Evidence map›Paper›PMID 34626567›Full record

ArticleMolecular cell2021

Terminal modification, sequence, length, and PIWI-protein identity determine piRNA stability.

Ildar Gainetdinov, Cansu Colpan, Katharine Cecchini, Amena Arif, Karina Jouravleva, Paul Albosta, Joel Vega-Badillo, Yongjin Lee, Deniz M Özata, Phillip D Zamore

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
8.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Reproductive phasiRNAs are the piRNAs of plants.Trends in genetics : TIG · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ildar GainetdinovRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA. Electronic address: ildar.gainetdinov@umassmed.edu.
Cansu ColpanRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Katharine CecchiniRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Amena ArifRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Karina JouravlevaRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Paul AlbostaRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Joel Vega-BadilloRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Yongjin LeeRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Deniz M ÖzataRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA.
Phillip D ZamoreRNA Therapeutics Institute and Howard Hughes Medical Institute, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA. Electronic address: phillip.zamore@umassmed.edu.
Howard Hughes Medical Institute · US

Funding

Understanding the architecture, regulation, and function of piRNA-producing genesP01HD078253 · NICHD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WENG, ZHIPING · 2015 to 2019
$6.5M
Understanding microRNA Biogenesis and FunctionR01GM065236 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ZAMORE, PHILLIP D · 2003 to 2014
$5.0M
Understanding the Evolution, Biology, and Molecular Mechanism of Argonaute ProteinsR35GM136275 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PHILLIP D ZAMORE · 2020 to 2026
$3.3M
BD FACSAriaTM Fusion Fluoresence-Activated Cell SorterS10OD028576 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHRADER, CAROL E · 2020 to 2020
$565k
Howard Hughes Medical InstituteNICHD NIH HHS P01 HD078253NIGMS NIH HHS R01 GM065236NIGMS NIH HHS R35 GM136275NIH HHS S10 OD028576
6 · The paper itself

Abstract

In animals, PIWI-interacting RNAs (piRNAs) silence transposons, fight viral infections, and regulate gene expression. piRNA biogenesis concludes with 3' terminal trimming and 2'-O-methylation. Both trimming and methylation influence piRNA stability. Our biochemical data show that multiple mechanisms destabilize unmethylated mouse piRNAs, depending on whether the piRNA 5' or 3' sequence is complementary to a trigger RNA. Unlike target-directed degradation of microRNAs, complementarity-dependent destabilization of piRNAs in mice and flies is blocked by 3' terminal 2'-O-methylation and does not require base pairing to both the piRNA seed and the 3' sequence. In flies, 2'-O-methylation also protects small interfering RNAs (siRNAs) from complementarity-dependent destruction. By contrast, pre-piRNA trimming protects mouse piRNAs from a degradation pathway unaffected by trigger complementarity. In testis lysate and in vivo, internal or 3' terminal uridine- or guanine-rich tracts accelerate pre-piRNA decay. Loss of both trimming and 2'-O-methylation causes the mouse piRNA pathway to collapse, demonstrating that these modifications collaborate to stabilize piRNAs.

Indexed as

AnimalsArgonaute ProteinsCell SeparationDrosophila melanogasterFemaleFlow CytometryGene ExpressionGene SilencingGenetic TechniquesMaleMethylationMiceMice, Inbred C57BLMice, TransgenicProtein Processing, Post-TranslationalRNA, Double-StrandedArgonaute ProteinsRNA, Double-StrandedRNA, Small Interfering2'-O-methylationpiRNAPIWIpiwi-interacting RNARNA stabilityRNA turnoversiRNAsmall interfering RNAsmall RNAtarget-directed microRNA degradation

Identifiers

PMID34626567
PMCPMC8642287
OpenAlexW3202373700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.